Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-01-11

Opinion for Teva Pharmaceutical (TEVA-N)

Signal Price Bias Subject Owned
DON'T BUY $34.280 UNKNOWN NORTH AMERICAN - LARGE No

A generic manufacturer, but do have some branded drugs. The company has been experiencing quite a bit of competition on one of their key branded drugs, so the profit growth is very uncertain, and the share price responded accordingly. There is just not enough clarity going forward.

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management

No Comments.


You must be logged in to comment.